Kiniksa: First Quarter 2023 Financial Results and Recent Portfolio Execution

 – ARCALYST® (rilonacept) Q1 2023 net product revenue of $42.7 million –

– ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint –
– Final cohort of KPL-404 Phase 2 rheumatoid arthritis trial now enrolling patients; data expected in 1H 2024 –
– Cash reserves now expected to fund operations into at least 2026 –
– Conference call and webcast scheduled for 8:30 am ET today –

Conference Call Information

• Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, May 2, 2023 to discuss first quarter 2023 financial results and recent portfolio execution.

• Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

https://finance.yahoo.com/news/kiniksa-pharmaceuticals-reports-first-quarter-113000936.html